#USA #Cambrex #East Rutherford #Snapdragon #Song Lin

Cambrex Announces Professor Song Lin as the 2025 Snapdragon Prize Winner

Cambrex, a global leader in contract development and manufacturing organization (CDMO), along with its subsidiary Snapdragon Chemistry, proudly reveals that Professor Song Lin from Cornell University has been awarded the Snapdragon Prize for Innovation in Chemical Technology for 2025. This award comes with an unrestricted $50,000 grant aimed to bolster research at the Lin Lab.

Professor Lin's groundbreaking contributions to electrosynthetic chemistry have opened innovative pathways in utilizing electrochemistry for pharmaceutical product development and manufacturing. His lab specializes in advancing organic chemistry, electrosynthesis, catalysis, and technological development. Lin’s recent initiatives in sustainable electrochemical techniques for synthesizing complex organic molecules—especially crucial chiral compounds—have set new benchmarks for efficiency and environmental responsibility in the field.

Matthew Bio, Chief Scientific Officer at Cambrex, emphasized the company’s commitment to advancing pharmaceutical science through collaboration and innovation, stating, "Professor Lin’s pioneering work in electrosynthetic chemistry embodies the spirit of the Snapdragon Prize and our dedication to supporting transformative research that will define the future of drug discovery and manufacturing."

Over the years, Professor Lin has amassed numerous accolades, including being a finalist for the 2025 Blavatnik National Awards, the 2023 Arthur C. Cope Scholar Award, and recognition as a Highly Cited Researcher by Clarivate in 2025, along with winning the 2022 Green Chemistry Challenge Award. These honors reflect his unwavering leadership and significant impact on the scientific community.

Established in 2024 by Snapdragon Chemistry, the Snapdragon Prize honors an outstanding academic researcher in synthetic chemistry or engineering each year. This award recognizes work that holds the potential to significantly influence the discovery and manufacturing of pharmaceutical products. The inaugural award was presented to Professor Todd Hyster and the Hyster Lab at Princeton University, highlighting Cambrex's commitment to scientific excellence and innovation in developing complex small molecules, thereby fostering the next generation of advancements in pharmaceutical science.

About Cambrex

Cambrex is a global leader in CDMO services, providing comprehensive development and manufacturing of pharmaceutical substances across their lifecycle, including comprehensive analytical services and IND enabling capabilities. With more than 45 years of experience and a team of 2,000 experts, Cambrex caters to clients across North America and Europe. The company offers a broad range of specialized pharmaceutical substance technologies and capabilities, including continuous flow, controlled substances, peptide synthesis, solid-state science, material characterization, and highly potent APIs.

For more information, please visit Cambrex.